ESR2 and breast carcinoma: In conclusion, our findings indicate that markers including ESR2, TOMM20, NFE2L2, and CAT not only play a role in mitochondrial oxidative stress but may also influence drug response and cancer recurrence, making them promising biomarkers to predict prognosis in luminal breast cancer.